Atopic Dermatitis
Conditions
Keywords
JAK Inhibitor, Atopic Dermatitis (AD), Abrocitinib, Eczema
Brief summary
The purpose of this study is to learn about the safety and effectiveness (how well the study treatment works) of the study medicine (CIBINQO) for the potential treatment of atopic dermatitis in people under Japanese medical practice.
Interventions
DRUGCIBINQO
Patients receiving CIBINQO tablets by mouth for the treatment of Atopic Dermatitis.
Sponsors
Pfizer
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
12 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Participants receiving this Product for treatment of AD. 2. Participants start receiving this Product (commercial product) for the first time and no earlier than the contract date of this Study, or Participants who continues to receive this drug after hospital transfer can be registered retrospectively.
Exclusion criteria
1\. Participants previously enrolled in this Study at the same site.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of Participants with adverse drug reactions | 156 weeks |
| Number of Participants with Discontinuation of Treatment | 156 weeks |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Participants Achieving Investigator's Global Assessment (IGA) Score | Baseline, 156 weeks | IGA Scores: Clear (0) or Almost Clear (1) and a Reduction From Baseline of Greater Than or Equal to ( \>=2) Points at Week X: Non-responder Imputation |
| Percentage of Participants with Change From Baseline in Eczema Area and Severity Index (EASI) | Baseline, 156 weeks | — |
| Percentage of Participants with Change From Baseline in Affected % Body Surface Area (BSA) | Baseline, 156 weeks | — |
| Percentage of Participants with Change From Baseline in Pruritus Assessment | Baseline, 156 weeks | — |
Countries
Japan
Contacts
STUDY_DIRECTORPfizer CT.gov Call Center
Pfizer
Outcome results
None listed